Healthcare stocks are mixed this afternoon, with the NYSE
Healthcare Sector Index rising about 0.2% while shares of
healthcare companies in the S&P 500 are slipping about 0.1 % as
In company news, Kythera Biopharmaceuticals Inc (
) is up nearly 25% at $41.85 a share, blowing past its former
52-week high to climb as high as $43.25 after saying its
experimental injectable drug succeeded in reducing double chin in
patients during late-stage studies.
Over 1000 patients with moderate to severe submental fat were
tested in the two studies conducted in the United States and
Canada, where ATX-101 was evaluated against a placebo and met both
its main and secondary clinical goals.
In other sector news,
(+) CRL, (-0.27.%) Initiated with a neutral rating at UBS and a
$49 price target, citing valuation. The research firm also said
there are early-stage signs of improvement at the
(-) RTMI, (-1.1%) FDA accepts Triferic as the trade name for the
company's investigational drug to treat iron deficiency.
Copyright (C) 2014 MTNewswires.com. All rights reserved. Unauthorized reproduction is strictly prohibited.